Physician profile
Timothy Brown
NPI 1932115821
$6,294.53
in general payments reported to CMS, 2019-2025
28 companies · $885 in 2025
The $885 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $198 · 2021: $1,200 · 2022: $1,611 · 2023: $734 · 2024: $812 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.35 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,409.29 | 2019-2024 | Skyrizi, Rinvoq |
| Merz North America, INC. | $736.36 | 2019-2023 | |
| Janssen Biotech, INC. | $542.38 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $529.00 | 2019-2025 | |
| Amgen INC. | $418.59 | 2019-2025 | Otezla, Otezla |
| Genentech USA, INC. | $381.79 | 2019-2023 | Erivedge |
| Journey Medical Corporation | $268.15 | 2022 | |
| Genzyme Corporation | $252.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.83 | 2022-2024 | Spevigo |
| Ucb, INC. | $216.35 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $204.54 | 2020-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $171.53 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $152.26 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.19 | 2022-2024 | Sotyktu |
| Pfizer INC. | $113.90 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.13 | 2019-2021 | |
| Lilly USA, LLC | $66.23 | 2019-2022 | |
| Misonix INC | $62.95 | 2019 | |
| Organogenesis INC. | $59.06 | 2022-2025 | Via Matrix |
| Helsinn Therapeutics (U.S.), INC. | $52.50 | 2019-2023 | Valchlor |
| Allergan, INC. | $43.11 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $43.10 | 2023-2025 | Zoryve |
| Dermira, INC. | $40.01 | 2019-2020 | |
| Almirall LLC | $23.23 | 2023 | Klisyri |
| Mimedx Group, INC. | $14.80 | 2025 | |
| Galderma Laboratories, L.P. | $13.49 | 2025 | |
| Biofrontera INC. | $13.43 | 2021 | |
| Kyowa Kirin, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.